Sargent Investment Group LLC bought a new stake in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 4,670 shares of the exchange traded fund’s stock, valued at approximately $569,000.
Other hedge funds also recently modified their holdings of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of SPDR S&P Biotech ETF in the 4th quarter valued at about $27,000. Intesa Sanpaolo Wealth Management bought a new position in shares of SPDR S&P Biotech ETF in the 4th quarter valued at about $30,000. Legacy Wealth Managment LLC ID bought a new position in shares of SPDR S&P Biotech ETF in the 4th quarter valued at about $32,000. Smartleaf Asset Management LLC bought a new position in shares of SPDR S&P Biotech ETF in the 4th quarter valued at about $32,000. Finally, Acumen Wealth Advisors LLC bought a new position in shares of SPDR S&P Biotech ETF in the 4th quarter valued at about $34,000.
SPDR S&P Biotech ETF Trading Up 2.0%
Shares of NYSEARCA XBI opened at $136.40 on Tuesday. The firm has a market capitalization of $8.70 billion, a PE ratio of 11.47 and a beta of 0.85. SPDR S&P Biotech ETF has a 1 year low of $80.90 and a 1 year high of $139.19. The firm’s 50-day moving average is $132.78 and its 200-day moving average is $127.28.
SPDR S&P Biotech ETF Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
See Also
- Five stocks we like better than SPDR S&P Biotech ETF
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
- Iran Ceasefire or Not, These 3 Companies Could Win
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
